ID | 59905 |
フルテキストURL | |
著者 |
Iwata, Hiroji
Okayama University Hospital
|
抄録 | Systemic therapies for operable breast cancer patients have improved outcomes and have thus become standard treatments. Recently, new molecular target drugs and regimens are being developed based on the predicted sensitivity for specific breast cancer histological types. Systemic therapy is selected according to recurrence risk, with the treatment for low-risk patients being de-escalated, while high-risk patients receive aggressive systemic treatment with an adequate dose and duration. Neoadjuvant systemic therapy has a different aim. The efficacy of systemic therapies, based on the sensitivities to drugs, is supported by improvements in the rate of breast-conserving therapy. The response to neoadjuvant systemic therapy is the most important factor for predicting outcomes and selecting the optimal adjuvant therapy. Novel biological markers unique to individual patients allow appropriate targeted therapy, which can achieve optimal efficacy.
|
キーワード | breast cancer
adjuvant
neoadjuvant
|
備考 | This is a pre-copyedited, author-produced version of an article accepted for publication in Japanese Journal of Clinical Oncology following peer review. The version of record TTadahiko Shien, Hiroji Iwata, Adjuvant and neoadjuvant therapy for breast cancer, Japanese Journal of Clinical Oncology, Volume 50, Issue 3, March 2020, Pages 225–229 is available online at: https://doi.org/10.1093/jjco/hyz213.
|
発行日 | 2020-01-28
|
出版物タイトル |
Japanese Journal of Clinical Oncology
|
巻 | 50巻
|
号 | 3号
|
出版者 | Oxford University Press
|
開始ページ | 225
|
終了ページ | 229
|
ISSN | 0368-2811
|
NCID | AA00690866
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | Copyright © 2020 Oxford University Press
|
論文のバージョン | author
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1093/jjco/hyz213
|
助成機関名 |
Japan Agency for Medical Research and Development
|
助成番号 | 19ck0106307h0002
|